Dep● of HEALTH, EDUCATION, AND ●LFA●● Pu●● Health Service

NATIONAL INSTITUTES OF HEALTH

2 October 1957

IN REPLYING ADDRESS THE
NATIONAL INSTITUTE OF MENTAL HEALTH
ADDICTION RESEARCH CENTER
U.S. PUBLIC HEALTH SERVICE HOSPITAL
P. O. BOX 2000

109

(b)(3)

I am enclosing three copies of a report "Studies on the Diethylamide of Lysergic Acid. III. Effects of Phenoxybenzamine on LSD-Reaction in Man." You will note that the pretreatment with phenoxybenzamine did not alter significantly the mental effects of 1 mcgm./kg. of LSD. We thought you would be interested in this information, and you may, of course, pass it on to any other persons who are working in the psychosomimetic field.

Recently I have been attempting to do the opposite. Rather than attempting to attenuate the LSD-reaction, I have attempted to accentuate it by administering epinephrine. So far, we have tried a combination of 1 mcgm./kg. of LSD plus 0.4 mg./70 kg. of epinephrine subcutaneously. There has been no evidence of any accentuation or blocking of the LSD-reaction as yet. The work is continuing and the dose of epinephrine will gradually be raised.

We are also initiating preliminary studies on d-lysergic acid morpholide, d-lysergic acid pyrrolidid, d-dimethylamide of lysergic acid, and 4-dihydro-lysergylamido-d-oxazolidone. All of these materials have been furnished to us by the Sandoz Company. The object of the experiments will be to obtain information on the relation of chemical changes in the LSD molecule to changes in psychosomimetic activity. The first experiments will be designed to get a rough approximation of the effective dose range in man, after which critical experiments comparing these two dose levels of each drug with two dose levels of LSD in the same subjects will be carried out.

With kindest personal regards,

Yours very sincerely,

Harris Isbell

Harris Isbell, M.D.
Director

HI:tkh

Enclosures

PS: Do you have anything on [illegible] of Lysergic acid?

A-392